《新股表现》欧康维视生物(01477.HK)暗盘收43.9元 每手账面赚14,620元
据辉立交易平台数据,明日(10日)上市的欧康维视生物-B(01477.HK)暗盘开报28元,较上市价14.66元高91%,其後升势扩大,最高见44元,收报43.9元,较上市价高199.5%或29.24元,成交765万股,涉3.13亿元。不计手续费,每手500股,账面赚14,620元。
公司为内地眼科医药平台,以上限定价(招股价介乎13.16至14.66元),公开发售录超购1,894.76倍,经重新分配後,公开发售股数占比增至50%。每手500股,中签率仅5%。摩根士丹利及高盛为联席保荐人。
欧康维视生物估计所得款项净额约14.24亿元,其中30%将用於核心产品OT-401;50%将用於其他候选药物;10%将用於根据与当地政府所订合作协议收购苏州的制造设施;及10%用作营运资金及用於其他一般公司用途等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.